Institute Pasteur Paris and PathoQuest | Date: 2017-05-17
The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcipts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.
Institute Pasteur Paris, National Veterinary School of Alfort, PathoQuest and Lassistance Publique Hopitaux De Paris | Date: 2015-07-07
The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.1.3-01 | Award Amount: 3.92M | Year: 2013
The project intends to address the risk of emerging viral vector borne diseases in two main categories of arthropods known to transmit important animal and zoonotic diseases: mosquitoes (Aedes and Culex), and Culicoides biting midges. A research proposal targeting potential emerging viral disease risks related to these vectors will be carried out through original and integrated multidisciplinary approaches including: - Study of virus and microbial communities by next-generation sequencing (NGS) methodsin vectors collected in targeted ecosystems, providing an unprecedented global understanding of the role of the microbial and environmental ecology in virus emergence and transmission. It will also permit the discovery of new potential pathogens and the development of innovative diagnostic methods for surveillance and new tools for intervention strategies; - Characterization of vector competence mechanisms in selected vector-virus couples, including mosquitoes / Rift Valley fever virus (RVFV) and Culicoides / Schmallenberg virus (SBV) and Orbiviruses; - Development of vector distribution and disease transmission models; - Development of better maps of high-risk areas for vector presence, as well as disease emergence and spread taking into account the impact of globalization, including climate changes and intensification of human and animal movements; - Design of new surveillance frameworks accounting for these new diagnostic methods, new knowledge and risk assessment analyses, for improved strategies of vectors, domestic and wild susceptible speciessurveillance by national and regional authorities; - Improvement of intervention strategies against vector borne diseases; Owing to this field of investigations, the project has a high potential for industrial and commercial outputs in Europethrough diagnostic kits, vaccines and computational software.
Institute Pasteur Paris, PathoQuest and National Veterinary School of Alfort | Date: 2011-11-25
The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.
Institute Pasteur Paris, University of Paris Descartes, Assistance Publique Hopitaux De Paris, PathoQuest and National Veterinary School of Alfort | Date: 2013-04-19
The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
PathoQuest and National Veterinary School of Alfort | Date: 2013-11-27
The invention relates to a method and a kit for in vitro differential treatment of nucleic acid molecules contained in a biological sample and comprising a first subpopulation of free nucleic acids of higher eukaryotic cells and at least one further subpopulation of nucleic acids of microorganism(s) wherein said microorganism(s) nucleic acids are packaged nucleic acids that represents quantitatively a minor group of the nucleic acids of the sample, comprising at least the steps of:a. exposing the biological sample to conditions enabling the modification of the 3- and/or 5- extremities of degraded nucleic acid molecules of the first nucleic acids subpopulation in order to impair their ligation capacity;b. extracting nucleic acid molecules of the sample and thereby recovering degraded nucleic acid molecules of the first nucleic acids subpopulation having modified 3- and/or 5- extremities and nucleic acid molecules of the further subpopulation having non-modified 3- and/or 5- extremities.
News Article | February 22, 2017
PARIS--(BUSINESS WIRE)--PathoQuest, a biotechnology company spun out from Institut Pasteur, announced today the on-line publication of results from the PATHOQUEST-1 study. The full manuscript, titled Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study, is available in Clinical Microbiology and Infection. PATHOQUEST-1 (NCT02007642) is an observational proof-of-concept study conducted in 2 reference hospitals -Necker-Enfants Malades and Européen-Georges Pompidou hospitals- (Paris, France). It enrolled 101 immunocompromised patients suspected of infection, and compared the performance of PathoQuest’s NGS-based metagenomics test and the conventional diagnostic pipeline to identify pathogens. PATHOQUEST-1 was run with a prototype version of the CE-IVD iDTECT Blood™ test. The 3 key components of the test -i.e. sample preparation, sequencing and data analysis- have been improved to reach the level of performance and validation required for CE marking. Specific steps of the test process have been patented or copyrighted and are proprietary. “This study demonstrates that the metagenomic test identified a relevant pathogen in more patients in a difficult-to-diagnose population than the conventional pipeline,” said Marc Eloit, PhD, Pathogen Discovery Laboratory at Institut Pasteur, Paris, France, a study investigator and founder and scientific advisor for PathoQuest. “These data underscore the potential of NGS to improve detection and identification of pathogens in routine diagnostic testing of biological samples including blood which is technically challenging.” “With the broader availability of sequencing platforms in clinical microbiology laboratories, metagenomics-based testing will increase our chances of identifying pathogens in infected patients and allow a better management of infectious diseases, especially in immunocompromised patients where the current diagnostic pipeline frequently fails to identify a responsible pathogen.” added Xavier Nassif, MD, PhD, Head of the Clinical Microbiology Laboratory, Necker-Enfants Malades Hospital, Paris, France, and a study investigator. “These study results should pave the way for such developments”. Immunocompromised patients have an impaired or weakened immune system resulting in an increased susceptibility to infection and reduced ability to efficiently respond to such situations. This inability to fight infections can be caused by a number of diseases (such as cancer or leukemia), or drugs (such as anti-cancer therapies or long term immune-suppressants used to prevent organ rejection). Prevalence of these conditions is increasing. Identifying the causative pathogen(s) in immunocompromised patients suspected of infection can be challenging. For instance, only 20 to 30% of blood cultures, the conventional diagnostic test in this clinical situation, are positive for a pathogen in patients developing febrile neutropenia following chemotherapy or stem cell transplantation (1,2,3). In most other cases, the infection remains of unknown origin, leading to the systematic use of broad spectrum instead of targeted antibiotics. Moreover, these patients are more susceptible to viruses or other microorganisms which have limited or no pathogenicity for non-immunocompromised subjects. Many also receive prophylactic or recurrent courses of antibiotics, making their pathogens difficult to grow in the lab. 1 Gyamarti et al, Scientific Reports, 2016 2 Freifeld et al, CID 2011 3 Gea-Banacloche, Hematology Am Soc Hematol Educ Program. 2013 PathoQuest, a spin out of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving pathogen detection in biological samples that overcomes the current limitation associated with pathogen detection. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. The company’s solution provides microbiologists and clinicians with a comprehensive analysis covering all known clinically relevant human pathogens. PathoQuest has developed iDTECT™ Blood Test, the first and only clinical CE IVD metagenomic test in infectious disease. Using a single blood sample, the test provides clinicians and microbiologists with an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test should improve antibiotic stewardship and lead to better patient care through precision medicine. Based on the company’s technological platform, PathoQuest also offers biopharmaceutical companies a disruptive approach to secure production of biologics like vaccines and recombinant proteins. PathoQuest’s solution is currently being utilized by several major biopharma companies for this purpose. To learn more about PathoQuest, visit www.pathoquest.com
News Article | October 27, 2016
PARIS--(BUSINESS WIRE)--PathoQuest Achieves CE Mark for the iDTECT™ Blood Test. iDTECT™ Blood is the first NGS-based metagenomics test to be CE-IVD marked for the clinical identification of pathogens from blood samples.
News Article | October 27, 2016
PARIS--(BUSINESS WIRE)--PathoQuest, une société de biotechnologie, spin off de l’Institut Pasteur, annonce aujourd’hui le marquage CE de iDTECT™ Blood. Ce test métagénomique novateur, basé sur la technologie NGS, permet d’élargir considérablement le spectre de détection des agents pathogènes. iDTECT Blood est un test basé sur une méthode exclusive allant de l’échantillon sanguin au rendu de résultats. Par rapport aux méthodes actuellement disponibles, il offre aux médecins une amélioration sign